Clinical Trial

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated February 25, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-10-31.
Trial Details
NCT Number NCT06112340
Lead Sponsor Sling Therapeutics, Inc.
Conditions Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases +4 more
Enrollment 75 participants
Start Date 2023-10-11
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-02-25